Tang et al., the STAT3 ASO activity was checked in phase II clinical trial conducted evaluating combination treatment with danvatirsen (ASO that inhibits STAT3) and durvalumab (anti-PD-L1) in patients NSCLC [42]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.